Video 2: Diagnosing Alzheimer’s:...

Explore how clinicians use cognitive tests, imaging, and biomarker tools to diagnose Alzheimer’s...

FSSAI Proposes Sugar Restrictions...

FSSAI proposes sugar restrictions in infant foods to protect our...

FDA Recalled Over 4.3...

More than 4.3 million toothpaste tubes have been recalled in...
HomeVIDEOSChanging the Narrative:...

Changing the Narrative: One Man’s Journey to Alzheimer’s Diagnosis and Treatment



Source:

Receiving a diagnosis of Alzheimer’s disease or a related dementia can be a complicated experience. While some experience relief at being able to put a name to their concerns, many worry about telling loved ones or being treated differently due to the stigma surrounding  the word “dementia.” Mike Zuendel joins the podcast to share his experience of being diagnosed with Mild Cognitive Impairment (MCI) due to Alzheimer’s disease and how he’s pushing back against the stigma surrounding dementia. He also talks about how early detection and starting treatment have allowed him to lead a normal life with cognitive impairment.
Guest: Mike Zuendel, member, board of directors, Banner Alzheimer’s Institute Foundation, member, Alzheimer’s Patient Advisory Board, Center for Information and Study on Clinical Research Participation, founder, Initiative to Change the D-Word, founder, CEO, Legacy Bridge Private Family Offices
 
Show Notes
Learn more about Mike Zuendel on his profile on the Initiative to Change the D-Word’s website:
Learn more about MCI by listening to other MCI-related episodes of Dementia Matters:
 
Connect with us
Find transcripts and more at our website:
Email Dementia Matters: dementiamatters@medicine.wisc.edu
Follow us on Facebook and Twitter:
Subscribe to the Wisconsin Alzheimer’s Disease Research Center’s e-newsletter:
Enjoy Dementia Matters? Consider making a gift to the Dementia Matters fund through the UW Initiative to End Alzheimer’s. All donations go toward outreach and production:

source

Continue reading

Video 2: Diagnosing Alzheimer’s: Clinical Criteria and Diagnostic Tools

Explore how clinicians use cognitive tests, imaging, and biomarker tools to diagnose Alzheimer’s accurately and efficiently. Series sponsored by Eisai. To watch the full series, visit aapa.org/VitalRounds References and Additional Resources: Alzheimer’s association statement on first blood test used in diagnosing...

Study defines average human genome and normal genetic disease risk

A new study has characterized the "average" human genome, providing key information on normal human genetic variation and genetic disease risk. Researchers at the University of Exeter...

FSSAI Proposes Sugar Restrictions in Infant Foods: Why It Matters

FSSAI proposes sugar restrictions in infant foods to protect our children's health. Discover why this initiative is crucial for our little ones!